Terminated PHASE1 INTERVENTIONAL 7-arm NCT05184218

Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19

A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Intranasal Plus Intraoral IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19

Sponsor: IGM Biosciences, Inc.

Conditions COVID-19 Healthy Volunteers

Interventions IGM-6268 Placebo

Updated 5 times since 2022 Last updated: Oct 12, 2022 Started: Jan 20, 2022 Primary completion: May 6, 2022 Completion: Jul 4, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor Decision

Other terminated trials from IGM Biosciences, Inc.

More terminations from IGM Biosciences, Inc.

Other COVID-19 trials with similar outcome

Browse all COVID-19 trials

Listed as NCT05184218, this PHASE1 trial focuses on COVID-19 and Healthy Volunteers and remains terminated or withdrawn. Sponsored by IGM Biosciences, Inc., it has been updated 5 times since 2022, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Nov 2022 — Jul 2024 [monthly]

Terminated PHASE1

Status: Recruiting → Terminated
Mar 2022 — Nov 2022 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Feb 2022 — Mar 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Jan 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

IGM Biosciences, Inc.

Data source: IGM Biosciences, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bloemfontein, South Africa